MXPA00013037A - Composicion estable para dosis oral de liberacion extendida. - Google Patents
Composicion estable para dosis oral de liberacion extendida.Info
- Publication number
- MXPA00013037A MXPA00013037A MXPA00013037A MXPA00013037A MXPA00013037A MX PA00013037 A MXPA00013037 A MX PA00013037A MX PA00013037 A MXPA00013037 A MX PA00013037A MX PA00013037 A MXPA00013037 A MX PA00013037A MX PA00013037 A MXPA00013037 A MX PA00013037A
- Authority
- MX
- Mexico
- Prior art keywords
- oral dosage
- extended release
- pseudoephedrine
- dosage composition
- release oral
- Prior art date
Links
- 238000013265 extended release Methods 0.000 title abstract 2
- JAUOIFJMECXRGI-UHFFFAOYSA-N Neoclaritin Chemical compound C=1C(Cl)=CC=C2C=1CCC1=CC=CN=C1C2=C1CCNCC1 JAUOIFJMECXRGI-UHFFFAOYSA-N 0.000 abstract 2
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 abstract 2
- 229960001271 desloratadine Drugs 0.000 abstract 2
- 230000036470 plasma concentration Effects 0.000 abstract 2
- 229960003908 pseudoephedrine Drugs 0.000 abstract 2
- KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 abstract 2
- CAVQBDOACNULDN-NRCOEFLKSA-N (1s,2s)-2-(methylamino)-1-phenylpropan-1-ol;sulfuric acid Chemical compound OS(O)(=O)=O.CN[C@@H](C)[C@@H](O)C1=CC=CC=C1.CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 CAVQBDOACNULDN-NRCOEFLKSA-N 0.000 abstract 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 abstract 1
- 230000000172 allergic effect Effects 0.000 abstract 1
- 230000001387 anti-histamine Effects 0.000 abstract 1
- 239000000739 antihistaminic agent Substances 0.000 abstract 1
- 208000010668 atopic eczema Diseases 0.000 abstract 1
- 239000007888 film coating Substances 0.000 abstract 1
- 238000009501 film coating Methods 0.000 abstract 1
- 230000004968 inflammatory condition Effects 0.000 abstract 1
- 239000000133 nasal decongestant Substances 0.000 abstract 1
- 229960004159 pseudoephedrine sulfate Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000001624 sedative effect Effects 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Otolaryngology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Toys (AREA)
- Cosmetics (AREA)
Abstract
Se describe una composicion para dosis oral solida de liberacion extendida revestida con una pelicula que contiene una descongestivo nasal, pseudoefedrina o su sal, por ejemplo, sulfato de pseudoefedrina en un nucleo efectivo como para proporcionar una concentracion en plasma maxima geometrica de pseudoefedrina entre alrededor de 345 ng/ml y alrededor de 365 ng/ml en un tiempo entre alrededor de 7.60 horas y alrededor de 8.40 horas y que tiene dos o tres revestimientos de pelicula sobre el nucleo, el segundo contiene una cantidad de antihistamina, no sedativa, desloratadina, efectiva como para proporcionar una concentracion en plasma maximo geometrica de desloratadina entre alrededor de 2.15 ng/ml y alrededor de 2.45 ng/ml en un tiempo entre alrededor de 4.0 horas y alrededor de 4.5 horas, y el uso de la composicion para tratar pacientes que muestran signos y sintomas asociados con las condiciones alergicas y/o inflamatorias de la piel y de las vias aereas.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17283699P | 1999-12-20 | 1999-12-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA00013037A true MXPA00013037A (es) | 2003-06-19 |
Family
ID=22629437
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA00013037A MXPA00013037A (es) | 1999-12-20 | 2000-12-20 | Composicion estable para dosis oral de liberacion extendida. |
Country Status (37)
| Country | Link |
|---|---|
| US (2) | US6979463B2 (es) |
| EP (2) | EP1112738B1 (es) |
| JP (3) | JP5042403B2 (es) |
| KR (2) | KR100936572B1 (es) |
| CN (3) | CN101081224B (es) |
| AR (1) | AR027033A1 (es) |
| AT (1) | ATE463240T1 (es) |
| AU (4) | AU2277101A (es) |
| BR (1) | BR0006403A (es) |
| CA (1) | CA2329217C (es) |
| CO (1) | CO5251435A1 (es) |
| CY (1) | CY1110693T1 (es) |
| CZ (1) | CZ302860B6 (es) |
| DE (1) | DE60044117D1 (es) |
| DK (1) | DK1112738T3 (es) |
| EC (1) | ECSP003836A (es) |
| EG (1) | EG23759A (es) |
| ES (1) | ES2341751T3 (es) |
| HU (1) | HUP0004988A3 (es) |
| ID (1) | ID28675A (es) |
| IL (1) | IL140450A (es) |
| MX (1) | MXPA00013037A (es) |
| MY (1) | MY130773A (es) |
| NO (1) | NO331645B1 (es) |
| NZ (1) | NZ509028A (es) |
| PE (1) | PE20010982A1 (es) |
| PL (1) | PL211573B1 (es) |
| PT (1) | PT1112738E (es) |
| RU (2) | RU2303440C2 (es) |
| SA (2) | SA06270069B1 (es) |
| SG (1) | SG109438A1 (es) |
| SI (1) | SI1112738T1 (es) |
| SK (1) | SK287684B6 (es) |
| TR (1) | TR200003787A2 (es) |
| TW (1) | TWI225414B (es) |
| WO (1) | WO2001045668A2 (es) |
| ZA (1) | ZA200007715B (es) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001045676A2 (en) | 1999-12-20 | 2001-06-28 | Schering Corporation | Extended release oral dosage composition |
| AU2277101A (en) | 1999-12-20 | 2001-07-03 | Schering Corporation | Stable extended release oral dosage composition |
| US7405223B2 (en) | 2000-02-03 | 2008-07-29 | Schering Corporation | Treating allergic and inflammatory conditions |
| US20030070584A1 (en) | 2001-05-15 | 2003-04-17 | Cynthia Gulian | Dip coating compositions containing cellulose ethers |
| CN1518448A (zh) * | 2001-06-20 | 2004-08-04 | ���鹫˾ | 用于治疗鼻充血和鼻塞的抗组胺剂 |
| US8309118B2 (en) | 2001-09-28 | 2012-11-13 | Mcneil-Ppc, Inc. | Film forming compositions containing sucralose |
| US8323692B2 (en) | 2002-02-21 | 2012-12-04 | Valeant International Bermuda | Controlled release dosage forms |
| NZ535455A (en) * | 2002-02-21 | 2009-08-28 | Biovail Lab Int Srl | Controlled release dosage forms |
| WO2004080461A2 (en) * | 2003-03-12 | 2004-09-23 | TEVA Gyógyszergyár Részvénytársaság | Stable pharmaceutical compositions of desloratadine |
| US20050013863A1 (en) | 2003-07-18 | 2005-01-20 | Depomed, Inc., A Corporation Of The State Of California | Dual drug dosage forms with improved separation of drugs |
| US20070116764A1 (en) * | 2003-12-01 | 2007-05-24 | Shigeyuki Marunaka | Method for treatment of solid pharmaceutical preparation prior to printing and solid pharmaceutical preparation subjected to treatment prior to printing |
| US20060110449A1 (en) * | 2004-10-25 | 2006-05-25 | Lorber Richard R | Pharmaceutical composition |
| US20060252831A1 (en) * | 2005-05-06 | 2006-11-09 | Christopher Offen | Method for the treatment of magnesium and potassium deficiencies |
| US20060252830A1 (en) * | 2005-05-06 | 2006-11-09 | Brandon Stephen F | Method for the treatment of magnesium and potassium deficiencies |
| US20070014855A1 (en) * | 2005-07-12 | 2007-01-18 | Rahul Gawande S | Stable desloratadine compositions |
| US20070036859A1 (en) * | 2005-08-11 | 2007-02-15 | Perry Ronald L | Sustained release antihistamine and decongestant composition |
| US7827042B2 (en) | 2005-11-30 | 2010-11-02 | The Invention Science Fund I, Inc | Methods and systems related to transmission of nutraceutical associated information |
| US8000981B2 (en) | 2005-11-30 | 2011-08-16 | The Invention Science Fund I, Llc | Methods and systems related to receiving nutraceutical associated information |
| US10296720B2 (en) | 2005-11-30 | 2019-05-21 | Gearbox Llc | Computational systems and methods related to nutraceuticals |
| US7927787B2 (en) | 2006-06-28 | 2011-04-19 | The Invention Science Fund I, Llc | Methods and systems for analysis of nutraceutical associated components |
| US7974856B2 (en) | 2005-11-30 | 2011-07-05 | The Invention Science Fund I, Llc | Computational systems and methods related to nutraceuticals |
| US20080210748A1 (en) | 2005-11-30 | 2008-09-04 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware, | Systems and methods for receiving pathogen related information and responding |
| US8297028B2 (en) | 2006-06-14 | 2012-10-30 | The Invention Science Fund I, Llc | Individualized pharmaceutical selection and packaging |
| US8340944B2 (en) | 2005-11-30 | 2012-12-25 | The Invention Science Fund I, Llc | Computational and/or control systems and methods related to nutraceutical agent selection and dosing |
| FR2894143B1 (fr) * | 2005-12-01 | 2008-05-02 | Pierre Fabre Medicament Sa | Composition a liberation prolongee de l'actif, son procede de preparation et son utilisation. |
| WO2007143158A2 (en) * | 2006-06-01 | 2007-12-13 | Schering-Plough Healthcare Products, Inc. | Sustained release pharmaceutical formulation comprising phenylephrine |
| NZ573174A (en) * | 2006-06-01 | 2012-01-12 | Msd Consumer Care Inc | Sustained release pharmaceutical dosage form containing phenylephrine |
| CN101472561A (zh) * | 2006-06-01 | 2009-07-01 | 先灵公司 | 去氧肾上腺素脉冲释放制剂和药物组合物 |
| BRPI0711871A2 (pt) * | 2006-06-01 | 2011-12-06 | Schering Corp | composições farmacêuticas para liberação sustentada de fenilefrina |
| JP2009543780A (ja) * | 2006-07-11 | 2009-12-10 | ミューチュアル ファーマシューティカル カンパニー，インク． | 制御放出製剤およびキット |
| EP2164472A1 (en) * | 2007-06-01 | 2010-03-24 | Schering-Plough Healthcare Products, Inc. | Pharmaceutical composition comprising a substrate and a coating containing an active ingredient and polyvinylalcohol |
| PE20091084A1 (es) * | 2007-12-07 | 2009-07-23 | Schering Plough Healthcare | Formulaciones farmaceuticas de fenilefrina y composiciones para absorcion transmucosal |
| US20120065221A1 (en) | 2009-02-26 | 2012-03-15 | Theraquest Biosciences, Inc. | Extended Release Oral Pharmaceutical Compositions of 3-Hydroxy-N-Methylmorphinan and Method of Use |
| WO2010143202A1 (en) * | 2009-06-09 | 2010-12-16 | Sun Pharmaceutical Industries Ltd. | Pharmaceutical composition |
| TR201009396A2 (tr) | 2010-11-11 | 2012-05-21 | Bi̇lgi̇ç Mahmut | Desloratadin granüller |
| DE102016107760B4 (de) * | 2016-04-26 | 2018-09-20 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Essbare Funktionsschichten und Überzüge auf Hybridpolymerbasis für Pharmazie und Lebensmittel |
| US20180187263A1 (en) | 2017-01-05 | 2018-07-05 | Iowa State University Research Foundation, Inc. | Kits for diagnostic detection and prevention of feedlot bovine respiratory disease |
| WO2022023463A1 (en) | 2020-07-30 | 2022-02-03 | Faes Farma, S.A. | Decongestant drug delivery system |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US100000A (en) | 1870-02-22 | Improved sun-bonnet for horses | ||
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US3940485A (en) | 1973-12-12 | 1976-02-24 | Levinson Harold N | Treatment and pre-treatment of dysmetric dyslexia by improving sequential scanning and ocular fixation abilities and therapeutic compounds |
| US4008796A (en) | 1974-03-26 | 1977-02-22 | General Concrete Of Canada Limited | Control method for feeding items on a conveyor |
| GB1548022A (en) | 1976-10-06 | 1979-07-04 | Wyeth John & Brother Ltd | Pharmaceutial dosage forms |
| US4282233B1 (en) | 1980-06-19 | 2000-09-05 | Schering Corp | Antihistaminic 11-(4-piperidylidene)-5h-benzoÄ5,6Ü-cyclohepta-Ä1,2Ü-pyridines |
| HU194864B (en) | 1984-02-15 | 1988-03-28 | Schering Corp | Process for production of 8-chlor-6,11-dihydro-11-(4-piperidilidene)-5h-benzo (5,6)-cyclo-hepta (1,2-b) pyridine and its salts |
| US4552899A (en) | 1984-04-09 | 1985-11-12 | Analgesic Associates | Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs |
| US4783465A (en) | 1984-04-09 | 1988-11-08 | Analgesic Associates | Cough/cold mixtures comprising non-sedating antihistamine drugs |
| SE8404467D0 (sv) | 1984-09-06 | 1984-09-06 | Ferrosan Ab | Controlled-release medical preparations |
| US4731447A (en) | 1985-05-13 | 1988-03-15 | Schering Corporation | Process for preparing piperidylidene dihydro-dibenzo(a,d)-cycloheptenes or aza-derivatives thereof |
| US4804666A (en) | 1985-08-14 | 1989-02-14 | Schering Corporation | Antiallergic 6,11-dihydro-11-(4-piperidylidene)-5H-benzo(5,6)cyclohepta(1,2-B)pyridines |
| JPS6396126A (ja) | 1986-10-13 | 1988-04-27 | Taisho Pharmaceut Co Ltd | 安定化組成物 |
| US5089496A (en) | 1986-10-31 | 1992-02-18 | Schering Corporation | Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies |
| US4777170A (en) | 1987-02-03 | 1988-10-11 | Heinrich William A | Method to prevent and treat the signs and symptoms of motion sickness |
| GB8707421D0 (en) * | 1987-03-27 | 1987-04-29 | Wellcome Found | Pharmaceutical formulations |
| US4863931A (en) | 1988-09-15 | 1989-09-05 | Schering Corporation | Antihistaminic fluoro substituted benzocycloheptapyridines |
| US5019591A (en) | 1989-02-17 | 1991-05-28 | Pennsylvania Research Corporation | Method for treating retinopathy and other small vessel disorders associated with diabetes |
| US4990535A (en) | 1989-05-03 | 1991-02-05 | Schering Corporation | Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine |
| NZ238629A (en) | 1990-06-22 | 1993-09-27 | Schering Corp | Bis-benzo- or benzopyrido-cyclohepta (where z is c, o, s or n) piperidine, piperidylidene or piperazine compounds, medicaments and methods of preparation |
| WO1992011034A1 (en) | 1990-12-18 | 1992-07-09 | The Wellcome Foundation Limited | Agents for potentiating the effects of antitumor agents and combating multiple drug resistance |
| PT100502A (pt) | 1991-05-20 | 1993-08-31 | Alza Corp | Composicoes farmaceuticas para aumentar a capacidade de permeacao na pele utilizando monolinoleato de glicerol |
| YU48263B (sh) | 1991-06-17 | 1997-09-30 | Byk Gulden Lomberg Chemische Fabrik Gmbh. | Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola |
| US5266331A (en) | 1991-11-27 | 1993-11-30 | Euroceltique, S.A. | Controlled release oxycodone compositions |
| IL104192A (en) * | 1992-02-17 | 1998-01-04 | Siegfried Ag Pharma | Pharmaceutical dosage forms having prolonged release rate of zero order of the active ingredient |
| ES2042421B1 (es) | 1992-05-22 | 1994-08-01 | Uriach & Cia Sa J | Procedimiento para la obtencion de la 8-cloro-11-*1-*(5-metil-3-piridil)metil*-4-piperidiliden*-6,11-dihidro-5h-benzo*5,6*ciclohepta*1,2-b*piridina. |
| US5314697A (en) | 1992-10-23 | 1994-05-24 | Schering Corporation | Stable extended release oral dosage composition comprising loratadine and pseudoephedrine |
| IT1264517B1 (it) | 1993-05-31 | 1996-09-24 | Ekita Investments Nv | Compressa farmaceutica atta al rilascio in tempi successivi dei principi attivi in essa veicolati |
| JP2646972B2 (ja) | 1993-11-01 | 1997-08-27 | 日本電気株式会社 | 多ビットメモリ |
| DE4442999A1 (de) | 1994-12-02 | 1996-06-05 | Hexal Pharma Gmbh | Pharmazeutische Zusammensetzung mit einem aktiven Loratidin-Metaboliten |
| US5595997A (en) | 1994-12-30 | 1997-01-21 | Sepracor Inc. | Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine |
| US5807579A (en) * | 1995-11-16 | 1998-09-15 | F.H. Faulding & Co. Limited | Pseudoephedrine combination pharmaceutical compositions |
| JP3220373B2 (ja) * | 1995-11-28 | 2001-10-22 | バイエル薬品株式会社 | 持続性ニフエジピン製剤 |
| NZ335078A (en) * | 1996-10-31 | 2000-10-27 | Schering Corp | Composition, for the treatment of asthma, containing loratadine and a decongestant |
| PE71699A1 (es) * | 1997-02-07 | 1999-08-03 | Sepracor Inc | Composicion farmaceutica de descarboetoxiloratadina sin lactosa, no higroscopica y anhidra |
| US5900421A (en) | 1997-02-11 | 1999-05-04 | Sepracor Inc. | Methods and compositions for treating allergic asthma and dermatitis using descarboethoxyloratadine |
| US5939426A (en) | 1997-02-28 | 1999-08-17 | Sepracor Inc. | Methods for treating urinary incontinence using descarboethoxyloratadine |
| US6506767B1 (en) | 1997-07-02 | 2003-01-14 | Schering Corporation | 8-chloro-6,11-dihydro-11-(4-piperidylidine)-5H-benzo[5,6]cyclohepta[1-2-b] pyridine |
| US6270796B1 (en) | 1997-10-29 | 2001-08-07 | Robert E. Weinstein | Antihistamine/decongestant regimens for treating rhinitis |
| US6132758A (en) | 1998-06-01 | 2000-10-17 | Schering Corporation | Stabilized antihistamine syrup |
| CN1145485C (zh) | 1998-07-10 | 2004-04-14 | 先灵公司 | 8-氯-6,11-二氢-11-(4-亚哌啶基)-5H-苯并[5,6]环庚三烯并[1,2-b]吡啶口服组合物 |
| US6423721B1 (en) | 1998-09-10 | 2002-07-23 | Schering Corporation | Methods and compositions for treating sinusitis, otitis media and other related disorders using antihistamines |
| US6521254B2 (en) | 1998-12-07 | 2003-02-18 | J-Med Pharmaceuticals, Inc. | Single-dose antihistamine/decongestant formulations for treating rhinitis |
| US6051585A (en) | 1998-12-07 | 2000-04-18 | Weinstein; Robert E. | Single-dose antihistamine/decongestant formulations for treating rhinitis |
| US6100274A (en) | 1999-07-07 | 2000-08-08 | Schering Corporation | 8-chloro-6,11-dihydro-11- ](4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine oral compositions |
| US6114346A (en) * | 1999-10-22 | 2000-09-05 | Schering Corporation | Treating sleep disorders using desloratadine |
| AU2277101A (en) | 1999-12-20 | 2001-07-03 | Schering Corporation | Stable extended release oral dosage composition |
| WO2001045676A2 (en) | 1999-12-20 | 2001-06-28 | Schering Corporation | Extended release oral dosage composition |
| US7405223B2 (en) | 2000-02-03 | 2008-07-29 | Schering Corporation | Treating allergic and inflammatory conditions |
| AR028502A1 (es) | 2000-02-03 | 2003-05-14 | Schering Corp | Tratamiento de condiciones inflamatorias alérgicas |
| US6372802B2 (en) | 2000-05-19 | 2002-04-16 | Alcon Universal Ltd. | Aniline disulfide derivatives for treating allergic diseases |
| US6599913B1 (en) | 2001-06-29 | 2003-07-29 | Schering Corporation | Treating allergic and inflammatory conditions |
-
2000
- 2000-12-19 AU AU22771/01A patent/AU2277101A/en not_active Abandoned
- 2000-12-19 SK SK1967-2000A patent/SK287684B6/sk not_active IP Right Cessation
- 2000-12-19 WO PCT/US2000/034412 patent/WO2001045668A2/en active Application Filing
- 2000-12-20 DK DK00311445.1T patent/DK1112738T3/da active
- 2000-12-20 ZA ZA200007715A patent/ZA200007715B/xx unknown
- 2000-12-20 TW TW089127375A patent/TWI225414B/zh not_active IP Right Cessation
- 2000-12-20 CN CN2006100944812A patent/CN101081224B/zh not_active Expired - Fee Related
- 2000-12-20 NZ NZ509028A patent/NZ509028A/xx not_active IP Right Cessation
- 2000-12-20 CN CNB001373005A patent/CN1211079C/zh not_active Expired - Fee Related
- 2000-12-20 MX MXPA00013037A patent/MXPA00013037A/es active IP Right Grant
- 2000-12-20 KR KR1020000079045A patent/KR100936572B1/ko not_active Expired - Lifetime
- 2000-12-20 CN CNA2005100713014A patent/CN1679569A/zh active Pending
- 2000-12-20 NO NO20006504A patent/NO331645B1/no not_active IP Right Cessation
- 2000-12-20 AT AT00311445T patent/ATE463240T1/de active
- 2000-12-20 AU AU72443/00A patent/AU781924B2/en not_active Ceased
- 2000-12-20 PL PL344715A patent/PL211573B1/pl not_active IP Right Cessation
- 2000-12-20 ID IDP20001115A patent/ID28675A/id unknown
- 2000-12-20 CO CO00096727A patent/CO5251435A1/es active IP Right Grant
- 2000-12-20 JP JP2000387828A patent/JP5042403B2/ja not_active Expired - Fee Related
- 2000-12-20 BR BR0006403-3A patent/BR0006403A/pt not_active Application Discontinuation
- 2000-12-20 EP EP00311445A patent/EP1112738B1/en not_active Expired - Lifetime
- 2000-12-20 CA CA002329217A patent/CA2329217C/en not_active Expired - Fee Related
- 2000-12-20 AR ARP000106790A patent/AR027033A1/es not_active Application Discontinuation
- 2000-12-20 EC EC2000003836A patent/ECSP003836A/es unknown
- 2000-12-20 EP EP10159005A patent/EP2196195A3/en not_active Withdrawn
- 2000-12-20 HU HU0004988A patent/HUP0004988A3/hu unknown
- 2000-12-20 ES ES00311445T patent/ES2341751T3/es not_active Expired - Lifetime
- 2000-12-20 DE DE60044117T patent/DE60044117D1/de not_active Expired - Lifetime
- 2000-12-20 RU RU2000131898/15A patent/RU2303440C2/ru not_active IP Right Cessation
- 2000-12-20 PE PE2000001371A patent/PE20010982A1/es not_active Application Discontinuation
- 2000-12-20 MY MYPI20005989A patent/MY130773A/en unknown
- 2000-12-20 EG EG20001571A patent/EG23759A/xx active
- 2000-12-20 SG SG200007531A patent/SG109438A1/en unknown
- 2000-12-20 SI SI200031059T patent/SI1112738T1/sl unknown
- 2000-12-20 PT PT00311445T patent/PT1112738E/pt unknown
- 2000-12-20 TR TR2000/03787A patent/TR200003787A2/xx unknown
- 2000-12-20 CZ CZ20004812A patent/CZ302860B6/cs not_active IP Right Cessation
- 2000-12-20 IL IL140450A patent/IL140450A/en not_active IP Right Cessation
-
2001
- 2001-02-25 SA SA06270069A patent/SA06270069B1/ar unknown
- 2001-02-25 SA SA01210741A patent/SA01210741B1/ar unknown
-
2002
- 2002-06-19 US US10/175,460 patent/US6979463B2/en not_active Expired - Lifetime
-
2005
- 2005-08-22 AU AU2005203771A patent/AU2005203771A1/en not_active Abandoned
- 2005-10-06 US US11/244,743 patent/US7820199B2/en not_active Expired - Fee Related
-
2007
- 2007-02-02 RU RU2007104095/15A patent/RU2423106C9/ru not_active IP Right Cessation
- 2007-12-14 JP JP2007324054A patent/JP2008081510A/ja active Pending
-
2009
- 2009-02-06 AU AU2009200460A patent/AU2009200460B2/en not_active Ceased
-
2010
- 2010-06-07 CY CY20101100503T patent/CY1110693T1/el unknown
-
2011
- 2011-02-23 KR KR1020110016213A patent/KR101234940B1/ko not_active Expired - Fee Related
-
2012
- 2012-08-17 JP JP2012181028A patent/JP2012224642A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA00013037A (es) | Composicion estable para dosis oral de liberacion extendida. | |
| NO951527L (no) | Stabilt, oralt doseringspreparat med forlenget frigivelse | |
| BG106095A (en) | Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics | |
| MX9402938A (es) | Composicion terapeutica que comprende nicotinamida-adenina-dinucleotido ynicotinamida-adenina-fosfato-dinucleotido, estable ingerible y absorbible. | |
| TR200000129T2 (tr) | Yepyeni spiroazabisiklik heterosiklik bileşikler. | |
| BR0113710A (pt) | Compostos, processo para a preparação e utilização dos mesmos, composição farmacêutica, processo para o tratamento e profilaxia de artrite, enfermidades cardiovasculares, diabetes, insuficiência renal, distúrbios alimentares e obesidade | |
| AU684059B2 (en) | Application of riluzole in the treatment of Parkinson's disease and Parkinsonian syndromes | |
| FI972781A7 (fi) | Deskarboetoksiloratadiinin (DCL) tai sen farmaseuttisesti hyväksyttävän suolan käyttö valmistettaessa farmaseuttista tuotetta | |
| BG104620A (en) | Oral pharmaceutical extended release dosage form | |
| DE60128912D1 (en) | Pyridoxin- und pyridoxalanaloga als cardiovasculäre therapeutika | |
| NO994165L (no) | Anvendelse av deskarboetoksyloratadin for fremstilling av et medikament for behandling av urininkontinens, reisesyke og svimmelhet | |
| EE9800132A (et) | 1-(2-naft-2-üületüül)-4-(3-trifluorometüülfenüül)-1,2,3,6,-tetrahüdropüridiini kasutamine ravimite valmistamiseks amüotroofilise lateraalskleroosi raviks | |
| HRP950414B1 (en) | New compounds with analgetic and local anaesthetic effect | |
| HK1046089A1 (zh) | 褪黑激素的治療用途 | |
| AU7439996A (en) | Novel uses of mammalian ctla-8 and related reagents | |
| AU4937499A (en) | Use of succinic acid or salts thereof and method of treating insulin resistance | |
| DE69428276D1 (de) | Insulinähnlicher wachstumfaktor ii als antitumormittel | |
| UA36576A (uk) | Спосіб корекції реактивності організму у хворих на інфаркт міокарда в гострому та підгострому періодах |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration | ||
| HC | Change of company name or juridical status |